|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, et al: Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening and treatment) to reduce
future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yee YK, Tan VP, Chan P, Hung IF, Pang R
and Wong BC: Epidemiology of colorectal cancer in Asia. J
Gastroenterol Hepatol. 24:1810–1816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levin B, Lieberman DA, McFarland B, Smith
RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR,
et al: Screening and surveillance for the early detection of
colorectal cancer and adenomatous polyps, 2008: A joint guideline
from the American Cancer Society, the US Multi-Society Task Force
on Colorectal Cancer and the American College of Radiology. CA
Cancer J Clin. 58:130–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schrag D: The price tag on
progress-chemotherapy for colorectal cancer. N Engl J Med.
351:317–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lievre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alan P and Venook DN: Impact of primary
(1º) tumor location on overall survival (OS) and progression-free
survival (PFS) in patients (pts) with metastatic colorectal cancer
(mCRC): Analysis of CALGB/SWOG 80405 (Alliance) [Abstract]. 2016
ASCO Annual Meeting. 34:pp. 35042016;
|
|
9
|
Alan P and Venook DN: Impact of primary
(1º) tumor location on Overall Survival (OS) and Progression Free
Survival (PFS) in patients (pts) with metastatic colorectal cancer
(mCRC): Analysis of All RAS wt patients on CALGB/SWOG 80405
(Alliance) [Abstract]. ESMO Congress. 2016; [Abstract]. ESMO
Congress, 2016.
|
|
10
|
Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH,
Fidler IJ and Hung MC: Survival of cancer cells is maintained by
EGFR independent of its kinase activity. Cancer Cell. 13:385–393.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ,
Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF and Wang F:
Overexpression of SGLT1 and EGFR in colorectal cancer showing a
correlation with the prognosis. Med Oncol. 28 Suppl 1:S197–S203.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang MX, Hua YJ, Wang HY, Zhou L, Mai HQ,
Guo X, Zhao C, Huang WL, Hong MH and Chen MY: Long-term prognostic
implications and therapeutic target role of hexokinase II in
patients with nasopharyngeal carcinoma. Oncotarget. 7:21287–21297.
2016.PubMed/NCBI
|
|
14
|
Grizzle E.: J: Continuity Correction in
the χ 2 -Test for 2×2 Tables. 1967.
|
|
15
|
Sun X, Sun Z, Zhu Z, Guan H, Zhang J,
Zhang Y, Xu H and Sun M: Clinicopathological significance and
prognostic value of lactate dehydrogenase A expression in gastric
cancer patients. PLoS One. 9:e910682014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Girgis H, Masui O, White NM, Scorilas A,
Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AH, Bjarnason
GA, et al: Lactate dehydrogenase A is a potential prognostic marker
in clear cell renal cell carcinoma. Mol Cancer. 13:1012014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang ZF, Feng XS, Chen H, Duan ZJ, Wang
LX, Yang D, Liu PX, Zhang QP, Jin YL, Sun ZG and Liu H: Prognostic
significance of synergistic hexokinase-2 and beta2-adrenergic
receptor expression in human hepatocelluar carcinoma after curative
resection. BMC Gastroenterol. 16:572016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patra KC, Wang Q, Bhaskar PT, Miller L,
Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, et al:
Hexokinase 2 is required for tumor initiation and maintenance and
its systemic deletion is therapeutic in mouse models of cancer.
Cancer Cell. 24:213–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G
and Roh JK: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang X, Li X and Xie X, Ye F, Chen B,
Song C, Tang H and Xie X: High expressions of LDHA and AMPK as
prognostic biomarkers for breast cancer. Breast. 30:39–46. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Bougioukas G, Didilis V, Gatter KC and Harris AL; Tumour and
Angiogenesis Research Group, : Lactate dehydrogenase-5 (LDH-5)
overexpression in non-small-cell lung cancer tissues is linked to
tumour hypoxia, angiogenic factor production and poor prognosis. Br
J Cancer. 89:877–885. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu R, Jiang M, Chen Z, Xu X, Hu H, Zhao X,
Gao X and Guo L: Lactate dehydrogenase 5 expression in Non-Hodgkin
lymphoma is associated with the induced hypoxia regulated protein
and poor prognosis. PLoS One. 8:e748532013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang X, Liu M, Sun H, Wang F, Xie X, Chen
X, Su J, He Y, Dai Y, Wu H and Shen L: HK2 is a radiation resistant
and independent negative prognostic factor for patients with
locally advanced cervical squamous cell carcinoma. Int J Clin Exp
Pathol. 8:4054–4063. 2015.PubMed/NCBI
|
|
25
|
Ogawa H, Nagano H, Konno M, Eguchi H,
Koseki J, Kawamoto K, Nishida N, Colvin H, Tomokuni A, Tomimaru Y,
et al: The combination of the expression of hexokinase 2 and
pyruvate kinase M2 is a prognostic marker in patients with
pancreatic cancer. Mol Clin Oncol. 3:563–571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Wu K, Shi L, Xiang F, Tao K and
Wang G: Prognostic significance of the metabolic marker
hexokinase-2 in various solid tumors: A meta-analysis. PLoS One.
11:e01662302016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hamabe A, Yamamoto H, Konno M, Uemura M,
Nishimura J, Hata T, Takemasa I, Mizushima T, Nishida N, Kawamoto
K, et al: Combined evaluation of hexokinase 2 and phosphorylated
pyruvate dehydrogenase-E1α in invasive front lesions of colorectal
tumors predicts cancer metabolism and patient prognosis. Cancer
Sci. 105:1100–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
